Cargando…
Epoprostenol/hydroxychloroquine/tocilizumab: Acute large bowel perforation, off-label use and lack of efficacy: case report
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516240/ http://dx.doi.org/10.1007/s40278-020-83791-2 |
Ejemplares similares
-
Hydroxychloroquine/lopinavir/ritonavir/tocilizumab: Lack of efficacy following off label use: case report
Publicado: (2022) -
Tocilizumab: Off label use and lack of efficacy: case report
Publicado: (2021) -
Tocilizumab: Bowel perforation following off-label use: 2 case reports
Publicado: (2021) -
Alteplase/epoprostenol: Lack of efficacy: case report
Publicado: (2022) -
Remdesivir/tocilizumab: Lack of efficacy and off-label use: case report
Publicado: (2022)